Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARX-F02 for Cancer Breakthrough Pain
NCT00833040Phase 2Completed
- Sponsor
- Talphera
- Start
- Apr 2009
- Primary completion
- Mar 2010
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of sufentanil in breakthrough pain, sponsored by Talphera. Started Apr 2009; status: completed.
02
Drugs
sufentanil
03
Conditions
breakthrough pain
Beyond the preview
Go deeper on NCT00833040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00833040.